Bambusa Therapeutics

Transforming I&I Treatment with Next-Generation Bispecific Antibodies

Boston, United States · Founded 2024 · $90.0M raised

Employees
11–50
Founded
2024
Business Model
B2B
Total Funding
$90.0M
Last Round
$90.0M Series AFeb 2025
Rounds
2

About

Bambusa Therapeutics is developing next-generation bispecific antibodies for immunological and inflammatory (I&I) disorders, targeting conditions like atopic dermatitis, asthma, and COPD. The company's lead programs BBT001 and BBT002 use dual-pathway engineering to address the $40B+ Type 2 inflammatory dermatology market and the $80B+ Type 2 disorder market. Headquartered in Boston's Seaport district, Bambusa is backed by RA Capital, Janus Henderson, Redmile Group, and other leading life science investors.

Summary

Bambusa Therapeutics is a Biotech company based in Boston, United States, founded in 2024. It has raised $90.0M in total across 2 rounds, most recently a $90.0M Series A round in Feb 2025.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AFeb 2025
$90.0M

Sign up to see all 2 rounds

Seed through Series A — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Bambusa Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/bambusa-therapeutics"><img src="https://indexed.vc/api/badge/company/bambusa-therapeutics" alt="Bambusa Therapeutics on Indexed.vc" width="260" height="76" /></a>